PHF6

Across TCGA pan-cancer cohorts, PHF6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHF6 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PHF6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PHF6 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PHF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.264	0.886	.002	43	view →
LUAD	DFS	Quartile	III,IV	0.899	0.325	.026	8	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	4	view →
LSCC	OS	Median	II,III,IV	0.877	0.620	.018	4	view →
PDAC	DFS	Tertile	IV	0.558	0.225	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHF6–HNSC (DFS)

Open the HNSC breakdown →